Berlin, May 17, 2022, – Bayer will provide brand-new kidney and cardiovascular information from the thorough Kerendia ™ (finerenone) scientific trial program at the 59th European Renal Association (ERA) congress 2022. This brand-new information will consist of more insights from the FIDELITY prespecified pooled analysis, along with brand-new findings comparing finerenone results from FIDELIO-DKD with results from CREDENCE.
To see the total abstracts, please check out the ERA Congress Website, and download the Abstract Book.
Kerendia FIDELITY research study information:
A brand-new subgroup analysis from FIDELITY will exist at the 59th Age congress, examining the effectiveness and security of finerenone in clients with phase 4 CKD and T2D compared to clients with phase 1-3 CKD and T2D:
· Outcomes with Finerenone in Patients with Stage 4 Chronic Kidney Disease and Type 2 Diabetes: A Fidelity Subgroup Analysis
o MO198 – Mini-Oral Session Clinical Nephrology
o May 19, 2022; 08:00 am CEST, Mini-Orals Hall
o Abstract is released online in Nephrology Dialysis TransplantationVolume 37, Issue Supplement_3, May 2022, gfac066.100, https://doi.org/10.1093/ndt/gfac066.100
In addition, Bayer will display a brand-new post hoc FIDELITY analysis, assessing the impacts of Kerendia, a non-steroidal, selective mineralocorticoid receptor villain, in contrast with the steroidal mineralocorticoid receptor villain spironolactone (AldactoneTM± potassium binding representative, patiromer (VeltassaTMon serum potassium ([K[K+]results and discontinuations in a subgroup of clients that satisfy the eligibility requirements of the Phase II AMBER research study. The AMBER research study examined the impacts of spironolactone ± patiromer in 295 individuals.
· Finerenone in Resistant Hypertension in Moderate to Advanced CKD – A Post-Hoc Safety Analysis of FIDELITY
o MO1063 – Mini-Oral Session Clinical Nephrology
o May 19, 2022; 08:00 am CEST, Mini-Orals Hall
The prespecified pooled analysis FIDELITY, consisting of the Phase III research studies FIDELIO-DKD and FIGARO-DKD, makes up the biggest Phase III cardiorenal results scientific trial program examining cardiorenal results in >> 13,000 clients with CKD and T2D. Arise from FIDELITY were very first provided at the European Society of Cardiology (ESC) congress 2021 and released in November 2021 in the European Heart Journal
Kerendia FIDELIO-DKD research study information:
Bayer will provide brand-new matching-adjusted indirect contrast information of FIDELIO-DKD and the Phase III CREDENCE research study. FIDELIO-DKD examined the effectiveness and security of finerenone in contrast to placebo in addition to requirement of care on re